GlassScriptPhysician profile
Sohan Nagrani
NPI 1497132518
$20,030.44
in general payments reported to CMS, 2019-2025
38 companies · $5,523 in 2025
The $5,523 reported for 2025 was more than what 95% of Pain Medicine (Physical Medicine & Rehabilitation) providers received nationally (typical 2025 total: $400).
See the full distribution for Pain Medicine (Physical Medicine & Rehabilitation)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $300 · 2020: $542 · 2021: $2,932 · 2022: $2,466 · 2023: $2,355 · 2024: $5,913 · 2025: $5,523.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $11K · Travel and Lodging: $2,368.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $11,422.91 |
| Travel and Lodging | $2,367.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $4,141.23 | 2021-2025 | Synchromedii, Intellis Adaptivestim, Inceptiv |
| Abbott Laboratories | $3,601.16 | 2019-2025 | Proclaim, Eterna, Axium |
| Boston Scientific Corporation | $2,865.08 | 2021-2025 | General - Therapies, Wavewriter Alpha Prime 16, Intracept |
| Mml US, INC. | $1,970.68 | 2021-2025 | Reactiv8 |
| Si-Bone, INC. | $1,264.40 | 2023-2025 | |
| Globus Medical, INC. | $863.98 | 2025 | Senza, Vyrsa V1 |
| Vertos Medical, INC. | $678.39 | 2021-2024 | Mild Device Kit |
| Collegium Pharmaceutical, INC. | $594.65 | 2023-2025 | Xtampza, Belbuca |
| Stryker Corporation | $548.74 | 2024-2025 | Mild Device Kit, Optablate |
| Painteq LLC | $508.21 | 2024 | Painteq |
| Biotronik Nro, INC. | $361.80 | 2024-2025 | Prospera |
| Relievant Medsystems, INC. | $330.08 | 2019-2023 | Intracept |
| Nevro Corp. | $276.93 | 2020-2024 | Senza |
| Abbvie INC. | $232.30 | 2022-2025 | |
| Stimwave Technologies Incorporated | $208.61 | 2022 |
Show all 38 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Foundation Fusion Solutions, LLC | $208.23 | 2022-2024 | |
| Medtronic USA, INC. | $176.69 | 2019-2020 | |
| Fidia Pharma USA INC. | $159.81 | 2023-2025 | Hymovis |
| Nalu Medical, INC. | $110.52 | 2023 | Nalu Neurostimulation System |
| Averitas Pharma INC. | $106.27 | 2023-2024 | Qutenza |
| Medical Device Business Services, INC. | $100.75 | 2020 | |
| Pfizer INC. | $90.31 | 2023-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $88.57 | 2024-2025 | Relistor |
| Pacira Pharmaceuticals Incorporated | $71.81 | 2023-2024 | Iovera, Zilretta, Exparel |
| Tersera Therapeutics LLC | $69.86 | 2024 | Prialt |
| Spinal Simplicity, LLC | $66.28 | 2025 | Ha Minuteman G3-R |
| Curonix LLC | $62.43 | 2022-2023 | Pns Freedom-4a Permanent Neurostimulator Receiver Kit Channel A |
| Grt US Holding, INC. | $56.00 | 2022 | |
| Convatec INC. | $37.36 | 2025 | |
| Bioventus LLC | $22.91 | 2022 | |
| Azurity Pharmaceuticals, INC. | $22.00 | 2023 | Horizant |
| Merz North America, INC. | $21.34 | 2019 | |
| Redhill Biopharma INC. | $20.74 | 2022 | |
| Saluda Medical Americas, INC. | $20.44 | 2025 | Evoke |
| Scilex Pharmaceuticals INC. | $19.89 | 2024 | |
| Depuy Synthes Sales INC. | $19.40 | 2025 | Monovisc |
| Trice Medical, INC. | $16.46 | 2025 | |
| Valinor Pharma, LLC | $16.13 | 2025 | Movantik |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sohan Nagrani listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.